SGLT2 inhibitörü (Turkish Wikipedia)

Analysis of information sources in references of the Wikipedia article "SGLT2 inhibitörü" in Turkish language version.

refsWebsite

Global rank Turkish rank

4^th place

11^th place

2^nd place

4^th place

6^th place

6^th place

archive.org

Scheen (2014). "Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus". Drugs. 75 (1): 33-59. doi:10.1007/s40265-014-0337-y. PMID 25488697.

doi.org

Shubrook (2015). "Empagliflozin in the treatment of type 2 diabetes: Evidence to date". Drug Design, Development and Therapy. 9: 5793-803. doi:10.2147/DDDT.S69926. PMC 4634822 $2. PMID 26586935.
Usman (2018). "Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis". European Journal of Preventive Cardiology. 25 (5): 495-502. doi:10.1177/2047487318755531. PMID 29372664.
"Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence". Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 13: 161-174. 2020. doi:10.2147/DMSO.S233538. PMC 6982447 $2. PMID 32021362.
Scheen (2014). "Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus". Drugs. 75 (1): 33-59. doi:10.1007/s40265-014-0337-y. PMID 25488697.
Haas (2014). "Efficacy, safety and regulatory status of SGLT2 inhibitors: Focus on canagliflozin". Nutrition & Diabetes. 4 (11): e143. doi:10.1038/nutd.2014.40. PMC 4259905 $2. PMID 25365416.

nih.gov

ncbi.nlm.nih.gov

Shubrook (2015). "Empagliflozin in the treatment of type 2 diabetes: Evidence to date". Drug Design, Development and Therapy. 9: 5793-803. doi:10.2147/DDDT.S69926. PMC 4634822 $2. PMID 26586935.
Usman (2018). "Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis". European Journal of Preventive Cardiology. 25 (5): 495-502. doi:10.1177/2047487318755531. PMID 29372664.
"Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence". Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 13: 161-174. 2020. doi:10.2147/DMSO.S233538. PMC 6982447 $2. PMID 32021362.
Scheen (2014). "Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus". Drugs. 75 (1): 33-59. doi:10.1007/s40265-014-0337-y. PMID 25488697.
Haas (2014). "Efficacy, safety and regulatory status of SGLT2 inhibitors: Focus on canagliflozin". Nutrition & Diabetes. 4 (11): e143. doi:10.1038/nutd.2014.40. PMC 4259905 $2. PMID 25365416.